Physician profile
Eleanor R Weltge
NPI 1023636321
$25,195.35
in general payments reported to CMS, 2019-2025
22 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $1,387 · 2023: $5,118 · 2024: $4,711 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,757 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,030 · Consulting Fee: $5,535 · Travel and Lodging: $2,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,756.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,030.10 |
| Consulting Fee | $5,534.75 |
| Travel and Lodging | $2,017.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $10,215.14 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Ensite |
| Alnylam Pharmaceuticals INC. | $6,215.24 | 2022-2025 | Amvuttra, Onpattro |
| Bridgebio Pharma, INC. | $3,657.97 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals Lp | $1,929.79 | 2023-2025 | Wainua, Farxiga |
| Impulse Dynamics (USA) INC. | $976.31 | 2021-2025 | Optimizer, Optimizer |
| Pfizer INC. | $401.34 | 2021-2024 | |
| Cvrx, INC. | $326.71 | 2023-2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $316.73 | 2023-2024 | |
| Zoll Respicardia, INC. | $178.62 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $146.09 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $140.49 | 2022-2025 | |
| Novo Nordisk INC | $125.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.32 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.89 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $78.11 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $71.41 | 2023 | Endurant Iis |
| Edwards Lifesciences Corporation | $61.83 | 2021-2024 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $39.04 | 2022-2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $34.32 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, Ltd. | $28.43 | 2023 | Arcalyst |
| Tactile Systems Technology INC | $22.12 | 2024 | Flexitouch Plus, Entre Plus |
| Amgen INC. | $16.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleanor Weltge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.